Absence of Viral Complications When Using Rituximab to Treat TTP with Plasma Exchange
Bibliographic record
Abstract
Abstract INTRODUCTION Rituximab is widely used for the treatment of B cell lymphoma and, increasingly, for therapy in autoimmune diseases including TTP. One of the major concerns about this drug is that selectively depleting B-lymphocytes may increase the number of infections with reactivation of latent viruses such has Hepatitis B and Cytomegalovirus (CMV). Immunosuppression can result in increased susceptibility for HEV infection and chronic hepatitis. We have recently carried out a Phase II study in which Rituximabwas administered to 40 TTP patients with relapsing or refractory disease. These patients received very large volumes of non-inactivated plasma (range 50 to 110 litres), so it was considered possible that infection could occur. Therefore, we determined the viral status of the patients prior to, and after treatment. METHODS Forty patients, 20 refractory and 20 with relapsing TTP, were recruited from 4 apheresis centres. Each received 375 mg/m2 of Rituximab once a week for 4 weeks. Plasma exchange was initiated on day 0 and carried out daily for at least 7 of 10 days. Response to therapy was measured by platelet count. Tests for viral studies for hepatitis B core antigen and hepatitis E (which we recently reported to be transmitted during PE) were carried out at our National Viral Laboratories (location province). All but 1 patient who also got SDP received either cryosupernatant plasma or FFP in combination. Blood samples were taken on day 0 and repeated at 1, 12, 24 and 52 weeks for viral studies. RESULTS All patients decreased their CD20 values by week 2 and recovered fully by week 24. lgG levels were slightly decreased at week 2 in the relapsed patients but not in the refractory ones, then remained normal throughout testing. Three relapsing patients were strongly positive for anti-HEV at presentation however, the antibodies were all IgM negative ruling out recent infection. The HEV titres did not change during the period of assessment (52 weeks). One refractory patient was positive for anti-HEV lgG at 0 but negative by 4, 12 and 52 weeks. Two patients were weakly positive for anti-HEV. Of these, one refractory case showed a boost in titre at 24 weeks without producing lgM but no HEV RNA was found. At presentation, 3 other patients had borderline anti-HEV positive values. None of the 36 patients tested showed anti-HBc seroconversion for Hepatitis B at any point. Four weakly positive patients became negative. DISCUSSION Rituximab effectively caused immunosuppression in these TTP patients however, in spite of receiving very large volumes of untreated plasma, there was no evidence of overt infection or significant seroconversion except in the one case with an increase in IgG at 6 months. Immunoglobulin levels remained in the normal range in these patients because of the infusion of donor plasma suggesting a protective effect of the plasma and that maintenance of normal immunoglobulin levels through the use of IVIgG may be protective in other patients receiving Rituximab. Disclosures No relevant conflicts of interest to declare.
Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.
How this classification was reachedexpand
Full frame distilled prediction
Teacher imitationNot calibrated prevalence, not ground truth. Human validation pending. Learned from the 10,348 direct Codex labels and 10,348 direct Gemma labels. Candidate is the union of thresholded teacher heads; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels or direct frontier model labels.
Codex and Gemma teacher scores by category
| Category | Codex | Gemma |
|---|---|---|
| Metaresearch | 0.000 | 0.000 |
| Meta-epidemiology (narrow) | 0.000 | 0.000 |
| Meta-epidemiology (broad) | 0.000 | 0.000 |
| Bibliometrics | 0.000 | 0.000 |
| Science and technology studies | 0.000 | 0.000 |
| Scholarly communication | 0.000 | 0.000 |
| Open science | 0.000 | 0.000 |
| Research integrity | 0.000 | 0.000 |
| Insufficient payload (model declined to judge) | 0.000 | 0.000 |
Machine scores (provisional)
The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.
Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.
score_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from itClassification
machine, unvalidatedMachine predicted; a candidate call from one teacher head, not a consensus.
How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".